Hyde Marine Announces that Hyde GUARDIAN-US Ballast Water Treatment System has been submitted for USCG Type Approval

The Hyde GUARDIAN-US (Universal Service) has successfully completed all of the requirements of the Independent Laboratory and now is under review by the U.S. Coast Guard for Type Approval under 46CFR162.060

Pittsburgh, PA, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Hyde Marine, a wholly-owned subsidiary of Calgon Carbon Corporation, has announced that they have successfully submitted their application for U.S. Coast Guard (USCG) Type Approval of the Hyde GUARDIAN-US product in accordance with the requirements of 46 CFR 162.060-14.  This milestone represents the final step before the USCG’s final determination and indicates that the Independent Laboratory has accepted all testing and has recommended that the system meets the requirements for discharging ballast within the waters of the United States.

Testing of the system was conducted in challenging ‘sweet’ fresh water with less than 1 psu, with water down to a UVT level in the 40’s, and with the minimal holding times able to be processed by the test facility during the test cycles.  The system was also proven to have no potential for regrowth in the ballast tanks as many tests were conducted with extended hold times.

Hyde Marine is one of the world’s most successful ballast water treatment (BWT) technology companies with more than 500 of its ballast water treatment systems sold to date. The Hyde GUARDIAN-US BWTS uses space efficient filtration and ultraviolet disinfection to treat ships' ballast water to prevent the spread of invasive species from port to port. The design of the system closely mirrors the existing Hyde GUARDIAN-Gold product, and customers can easily upgrade their existing equipment to meet the new treatment standard.

“Hyde Marine is very pleased to have completed this process,” said Chris Todd, Executive Director of Calgon Carbon UV Technologies. “During shipboard testing, we used one of our first customers as an upgrade platform to prove we could retrofit one of our earliest systems to our newest product.  Our test plans proved a strenuous test of our system’s functionality, conclusively proving our ability to modulate flow to ensure proper dose, and demonstrating the effectiveness of our industry-exclusive Treatment Alarm.”